CA2991856A1 - Method for treatment of traumatic brain injury targeting aggregated peptides - Google Patents
Method for treatment of traumatic brain injury targeting aggregated peptides Download PDFInfo
- Publication number
- CA2991856A1 CA2991856A1 CA2991856A CA2991856A CA2991856A1 CA 2991856 A1 CA2991856 A1 CA 2991856A1 CA 2991856 A CA2991856 A CA 2991856A CA 2991856 A CA2991856 A CA 2991856A CA 2991856 A1 CA2991856 A1 CA 2991856A1
- Authority
- CA
- Canada
- Prior art keywords
- brain injury
- peptides
- traumatic brain
- agent
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195183P | 2015-07-21 | 2015-07-21 | |
| US62/195,183 | 2015-07-21 | ||
| US201662288813P | 2016-01-29 | 2016-01-29 | |
| US62/288,813 | 2016-01-29 | ||
| PCT/IB2016/054318 WO2017013599A1 (en) | 2015-07-21 | 2016-07-20 | Method for treatment of traumatic brain injury targeting aggregated peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2991856A1 true CA2991856A1 (en) | 2017-01-26 |
Family
ID=56550266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2991856A Abandoned CA2991856A1 (en) | 2015-07-21 | 2016-07-20 | Method for treatment of traumatic brain injury targeting aggregated peptides |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11327080B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3325506A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2018522891A (cg-RX-API-DMAC10.html) |
| CN (1) | CN107849125A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016295650A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2991856A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017013599A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006606B1 (ru) | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1827493A4 (en) * | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| SI2448968T1 (sl) | 2009-06-29 | 2021-07-30 | Bioarctic Ab | Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| EP2470211B1 (en) | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| AU2011326564A1 (en) * | 2010-11-10 | 2013-05-09 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
| US20150118231A1 (en) * | 2012-05-08 | 2015-04-30 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| EP2928494A4 (en) * | 2012-12-07 | 2016-11-02 | Biogen Internat Neuroscience Gmbh | METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES |
| US20160355573A1 (en) | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| US20150126390A1 (en) * | 2013-09-12 | 2015-05-07 | Washington University | Multiplex avidity profiling of protein aggregates |
| CN106661103B (zh) * | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
-
2016
- 2016-07-20 EP EP16742413.4A patent/EP3325506A1/en not_active Ceased
- 2016-07-20 AU AU2016295650A patent/AU2016295650A1/en not_active Abandoned
- 2016-07-20 US US15/746,283 patent/US11327080B2/en active Active
- 2016-07-20 WO PCT/IB2016/054318 patent/WO2017013599A1/en not_active Ceased
- 2016-07-20 JP JP2018503215A patent/JP2018522891A/ja active Pending
- 2016-07-20 CN CN201680042690.4A patent/CN107849125A/zh active Pending
- 2016-07-20 CA CA2991856A patent/CA2991856A1/en not_active Abandoned
-
2022
- 2022-05-13 JP JP2022079211A patent/JP2022113682A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022113682A (ja) | 2022-08-04 |
| EP3325506A1 (en) | 2018-05-30 |
| US11327080B2 (en) | 2022-05-10 |
| JP2018522891A (ja) | 2018-08-16 |
| US20180209994A1 (en) | 2018-07-26 |
| WO2017013599A1 (en) | 2017-01-26 |
| AU2016295650A1 (en) | 2018-01-25 |
| CN107849125A (zh) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022113682A (ja) | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 | |
| Reichenbach et al. | Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model | |
| Li et al. | Astrocyte-derived TNF-α-activated platelets promote cerebral ischemia/reperfusion injury by regulating the RIP1/RIP3/AKT signaling pathway | |
| US9730979B2 (en) | Methods for decreasing set in inhibiting protein phosphatase 2A (PP2A) and/or increasing the activity of cyclin-dependent kinase 5 (CDK5) by an APOE peptide | |
| Kaur et al. | Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics | |
| TWI873177B (zh) | 治療性融合蛋白 | |
| JP2015532592A5 (cg-RX-API-DMAC10.html) | ||
| HK1258529A1 (zh) | 用於治疗神经退行性和神经炎性病症的方法和组合物 | |
| WO2022198073A1 (en) | Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain | |
| Xu et al. | Association between pro-inflammatory cytokines in cerebrospinal fluid and headache in patients with aneurysmal subarachnoid hemorrhage | |
| Sano et al. | Intractable neurosarcoidosis effectively treated with infliximab | |
| US10889625B2 (en) | Peptide-based methods for treating neurological injury | |
| WO2021097407A2 (en) | Novel peptide compositions and methods of treating neurological injury | |
| WO2024114305A1 (en) | Oligonucleotide therapeutics and application thereof | |
| Toutonji | The Role of Complement in Traumatic Brain Injury | |
| Saxena et al. | High-Mobility Group Box-1 and Its Potential Role in Perioperative Neurocognitive Disorders. Cells 2021, 10, 2582 | |
| TW202506139A (zh) | 米韋爾西蘭（Ｍｉｖｅｌｓｉｒａｎ）組合物及其使用方法 | |
| WO2025184593A1 (en) | Tau-targeting therapy for alzheimer's disease and other tauopathies | |
| WO2023246847A1 (zh) | B2M-GluN1封闭肽、其药物组合物及用途 | |
| Sontheimer | MINI-REVIEW A role for glutamate in growth and invasion of primary brain tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20221012 |